Topic: Innovation
Taxing Jet Fuel Could Reduce Airline Greenhouse Gas Emissions Now
Breakthrough technologies are years off for aviation, but incremental improvements are available
‘They Were Already Inside My Head To Begin With’
The ethics of asking brain surgery patients to allow unrelated research while on the operating table
Mobile Banking, a Boon to Many, Disadvantages Those Who Bank at Branches
Banks close neighborhood outlets and raise prices for branch-delivered services
A Renter and Property Owner Meet on Airbnb: Will They Ditch the Site?
The risk for matching platforms is affected by levels of fees and what’s disclosed about buyer and seller
Amazon (and Other Platforms) vs. Third-Party Sellers: Complicated Debate
Some data shows competing against the platform can help sellers, if not consumers
Dividing Patients Between Telehealth, In-Office Primary Care and Referral to Specialists
Getting the mix right is the goal of a Medicare pilot, which itself could use substantial improvement
In a Boom, Incumbent Firms Can Redeploy Workers to Rapidly Expand
Startups lack bench strength, a disadvantage in tight labor markets
The Role of Chance Encounters in Silicon Valley Innovation
Cellphone signals and patent citations approximate a theory’s long-sought paper trail
College Completion and Your Genome (Don’t Get Too Excited)
It’s still early days in genetic research, though advances will aid study of educational attainment and, notably, disease
How Far Would You Go for an Ivy League Kid?
Study finds interest in screening embryos for education propensity, especially if everyone else is doing it
People Prioritize Shared Experiences, Even When Apart
People will endure inconvenience to synchronize events, regardless of proximity
Matching Algorithms Work Fine — Until Bypassed By External Links
How to rebalance supply and demand amid today’s chaotic internet traffic
FDA’s Breakthrough Program: Faster Drug OKs Without Sacrificing Safety
Dedicated FDA staff guide companies during design of clinical trials
Mandated Disclosure of Clinical Trials Ignored — Especially for Competitive Drugs
Pharma companies less likely to disclose critical drug information than public institutions